This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
=== Indoor ward === In second phase in April 2014, SIUT Chablani Medical center was upgraded to a full-fledged hospital, having 36-bed in its indoor ward. The indoor facilities reported 1,256 indoor admissions in same year and 33,918 patients went to the thrice-a-week outpatient clinic, 16,403 dialysis sessions were performed with 16 Hemodialysis machines, 2,400 patients received lithotripsy, the laboratory carried out 111,913 tests and 4,254 surgeries.
Deramciclane (developmental code names EGIS-3886, EXV-801) is an experimental drug which was studied for the treatment of anxiety disorders but was never marketed. It has since been repurposed for the treatment of agitation, both alone (as EXV-801) and in combination with dextromethorphan (DXM) (as EXV-802). The drug acts as a serotonin 5-HT2A receptor antagonist, serotonin 5-HT2C receptor inverse agonist, GABA reuptake inhibitor, and weak CYP2D6 inhibitor.
=== Health effects === Research starting in 1975 showed substantially increased risk of endometrial cancer. Since 1976, the drug has carried a label warning about the risk. As part of the Women's Health Initiative sponsored by the National Institutes of Health, a large-scale clinical trial of menopausal HRT showed that long-term use of estrogen and a progestin may increase the risk of strokes, heart attacks, blood clots, and breast cancer. Following these results, Wyeth experienced a significant decline in its sales of Premarin, Prempro (CEEs and medroxyprogesterone acetate), and related products, from over $2 billion in 2002 to just over $1 billion in 2006.
Sources: en.wikipedia.org
== Applications == Mass spectrometry imaging (MSI) can be used to map the spatial distribution of biomolecules in tissue without prior labeling of specific targets. It is used in clinical pharmacological research to examine changes in proteins, lipids and metabolites associated with the disease. Applications include biomarker identification, cancer research, studies of treatment response and evaluation of drug-delivery methods. Ion colocalization has been studied as a way to infer local interactions between biomolecules. Similarly to colocalization in microscopy imaging, correlation has been used to quantify the similarity between ion images and generate network models.
In 1842, John Gorrie created a system capable of refrigerating water to produce ice. Although it was a commercial failure, it inspired scientists and inventors around the world. France's Ferdinand Carre was one of the inspired and he created an ice producing system that was simpler and smaller than that of Gorrie. During the Civil War, cities such as New Orleans could no longer get ice from New England via the coastal ice trade. Carre's refrigeration system became the solution to New Orleans' ice problems and, by 1865, the city had three of Carre's machines. In 1867, in San Antonio, Texas, a French immigrant named Andrew Muhl built an ice-making machine to help service the expanding beef industry before moving it to Waco in 1871. In 1873, the patent for this machine was contracted by the Columbus Iron Works, a company acquired by the W.C. Bradley Co., which went on to produce the first commercial ice-makers in the United States. By the 1870s, breweries had become the largest users of harvested ice. Though the ice-harvesting industry had grown immensely by the turn of the 20th century, pollution and sewage had begun to creep into natural ice, making it a problem in the metropolitan suburbs. Eventually, breweries began to complain of tainted ice. Public concern for the purity of water, from which ice was formed, began to increase in the early 1900s with the rise of germ theory. Numerous media outlets published articles connecting diseases such as typhoid fever with natural ice consumption. This caused ice harvesting to become illegal in certain areas of the country.
Amphetamine, the active ingredient of Adderall, works primarily by increasing the activity of the neurotransmitters dopamine and norepinephrine in the brain. It also triggers the release of several other hormones (e.g., epinephrine) and neurotransmitters (e.g., serotonin and histamine) as well as the synthesis of certain neuropeptides (e.g., cocaine and amphetamine regulated transcript (CART) peptides). Both active ingredients of Adderall, dextroamphetamine and levoamphetamine, bind to the same biological targets, but their binding affinities (that is, potency) differ somewhat. Dextroamphetamine and levoamphetamine are both potent full agonists (activating compounds) of trace amine-associated receptor 1 (TAAR1) and interact with vesicular monoamine transporter 2 (VMAT2), with dextroamphetamine being the more potent agonist of TAAR1. Consequently, dextroamphetamine produces more CNS stimulation than levoamphetamine; however, levoamphetamine has slightly greater cardiovascular and peripheral effects. It has been reported that certain children have a better clinical response to levoamphetamine. In the absence of amphetamine, VMAT2 will normally move monoamines (e.g., dopamine, histamine, serotonin, norepinephrine, etc.) from the intracellular fluid of a monoamine neuron into its synaptic vesicles, which store neurotransmitters for later release (via exocytosis) into the synaptic cleft.
Sources: en.wikipedia.org
Ancient Iranians were among the first to invent a form of cooler utilizing the principles of evaporative cooling and radiative cooling called yakhchāls. These complexes used subterranean storage spaces, a large thickly insulated above-ground domed structure, and outfitted with badgirs (wind-catchers) and series of qanats (aqueducts). Pre-electric refrigeration In modern times, before the invention of the modern electric refrigerator, icehouses and iceboxes were used to provide cool storage for most of the year. Placed near freshwater lakes or packed with snow and ice during the winter, they were once very common. Natural means are still used to cool foods today. On mountainsides, runoff from melting snow is a convenient way to cool drinks, and during the winter one can keep milk fresh much longer just by keeping it outdoors. The word "refrigeratory" was used at least as early as the 17th century.
Immediately after the September 11 attack on the United States, President George W. Bush instructed Defense Secretary Donald Rumsfeld to come up with a plan to defeat the Taliban in Afghanistan who harbored Al Qaeda. General Tommy Franks, then-commanding general of Central Command, initially proposed a conventional force invasion of Afghanistan with 60,000 troops. He told Bush and Rumsfeld that it would take six months to launch the campaign. Rumsfeld heatedly rejected this plan, demanding that troops be sent in immediately. Franks returned the next day with a plan to utilize special forces, which Bush approved. For the 2001 invasion of Afghanistan, Task Force Dagger was established on 10 October 2001, the unit was built around the 5th SFG with helicopter support from the 160th SOAR, TF Dagger was assigned to northern Afghanistan and tasked with infiltrating ODA teams into Afghanistan to advise and support the commanders of the Northern Alliance. Task Force K-Bar was also established around a Naval Special Warfare Group consisting of SEAL Teams 2, 3, 8 and Green Berets from 1st Battalion 3rd SFG, the task force would primarily conduct special reconnaissance and site exploitation missions – intelligence gathering at former enemy locations, some 3rd SFG ODAs were also given the Foreign Internal Defence and Unconventional Warfare role. The TFs were part of the CJSOTF (Combined Joint Special Operations Task Force) under the overall leadership of General Tommy Franks, Coalition Forces Commander (CENTCOM) p. 25, p.
Following the outbreak of the COVID-19 pandemic, the NIH-funded EcoHealth Alliance has been the subject of controversy and increased scrutiny due to its ties to the Wuhan Institute of Virology (WIV)—which has been at the center of speculation since early 2020 that SARS-CoV-2 may have escaped in a lab incident. Between 2014 and 2019, NIH awarded approximately $3.7 million in grant funding to EcoHealth Alliance, a nonprofit organization focused on global health and infectious disease research. A portion of this funding, around $600,000, was subcontracted to WIV in China as part of a project titled "Understanding the Risk of Bat Coronavirus Emergence." The project aimed to study bat coronaviruses and assess their potential to infect humans. The research at WIV included the creation of chimeric viruses, which combined genetic material from different bat coronaviruses to evaluate their ability to infect human cells. In documents released in 2021, including NIH correspondence with Congress, it was disclosed that one of these modified viruses resulted in an "unexpected outcome," where the virus became more infectious in humanized mice. The NIH maintained that this outcome was not the intended goal of the research and did not violate the terms of the grant, though critics raised concerns about potential gain-of-function research. Under political pressure, the NIH withdrew funding to EcoHealth Alliance in July 2020. In 2023, HHS barred WIV from receiving U.S. government funding for a decade, citing non-compliance with safety and reporting standards.
The development of new technologies is increasing scientists' ability to analyze the genome and transcriptome of single cells, and to quantify their proteome and metabolome. Mass spectrometry techniques have become important analytical tools for proteomic and metabolomic analysis of single cells. Recent advances have enabled the quantification of thousands of proteins across hundreds of single cells, making possible new types of analysis. In situ sequencing and fluorescence in situ hybridization (FISH) do not require that cells be isolated and are increasingly being used for analysis of tissues.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.